Ert Pompe denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits Quantity for Pompe Disease ERT — and How to Appeal

Quantity-limit denials for enzyme replacement therapy in Pompe disease almost always reflect one of two mismatches: Humana's quantity-limit policy assumes a patient weight or dosing interval that does not match the specific patient's actual weight-derived dose under the FDA-approved prescribing label, or Humana's system approved a quantity at a prior body weight that has since changed. Because ERT for Pompe disease is dosed on a per-kilogram basis at a defined interval, any patient whose weight falls outside the plan's assumed range will routinely receive a quantity that is inadequate to complete an infusion cycle.

This denial is strongly appealable when the requested quantity is supported by a straightforward weight-based calculation using the FDA-approved label's dosing parameters.

## Federal Appeal Rights

Humana plans subject to ACA Section 2719 must provide internal appeal and, if denied, access to independent external review. ERISA Section 503 applies to employer-sponsored plans. External review must generally be requested within four months of the final internal adverse determination. Expedited review is available when the standard timeline would seriously jeopardize health — a missed or partial infusion in Pompe disease can result in measurable clinical regression, supporting urgency.

## What to Gather

• Current measured body weight — a dated weight from the clinical chart or most recent infusion record.
• Weight-based dose calculation — a written calculation, done by the prescriber or pharmacist, showing how the requested quantity derives from the patient's weight and the FDA label's dosing parameters. Reference the label directly.
• FDA-approved prescribing label — print the dosing section of the current label for the specific product; submit it as an exhibit.
• Humana's quantity-limit policy — obtain the current version from Humana's provider portal or medical-policy library and identify the basis for the quantity limit.
• Prescriber letter — the physician should confirm the patient's current weight, state the weight-based calculation, and explain that any quantity below the requested amount would result in an incomplete infusion cycle.
• Infusion administration records — prior records showing actual amounts administered per session, confirming clinical need for the requested quantity.

## Criteria-Mapping Structure

Create a side-by-side table: left column shows Humana's quantity-limit criteria; right column provides the patient's weight, the FDA-label calculation, and the resulting quantity required. If the limit is lower than what the label calculation produces, state explicitly that the limit does not accommodate the patient's weight-appropriate dose per the approved labeling.

## Process and Timeline

1. Before filing a full appeal, call Humana's pharmacy PA line — quantity-limit corrections tied to a weight update are sometimes resolved administratively. 2. If a formal appeal is required, file within the plan's deadline with the weight documentation, label calculation, and prescriber letter. 3. If denied internally, file for external review within four months. 4. Consider the expedited track if the patient is scheduled for an infusion and a partial-quantity approval would cause a treatment interruption.